Literature DB >> 15648955

Su-11248 Sugen.

Kathleen M Sakamoto1.   

Abstract

SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15648955

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  12 in total

1.  MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Authors:  Manik Chahal; Yaoxian Xu; David Lesniak; Kathryn Graham; Konrad Famulski; James G Christensen; Manish Aghi; Amanda Jacques; David Murray; Siham Sabri; Bassam Abdulkarim
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Authors:  Markus Hutterer; Martha Nowosielski; Johannes Haybaeck; Sabine Embacher; Florian Stockhammer; Thaddäus Gotwald; Bernhard Holzner; David Capper; Matthias Preusser; Christine Marosi; Stefan Oberndorfer; Martin Moik; Johanna Buchroithner; Marcel Seiz; Jochen Tuettenberg; Ulrich Herrlinger; Antje Wick; Peter Vajkoczy; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

4.  A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

Authors:  Eileen M O'Reilly; Donna Niedzwiecki; Margaret Hall; Donna Hollis; Tanios Bekaii-Saab; Timothy Pluard; Kathe Douglas; Ghassan K Abou-Alfa; Hedy L Kindler; Richard L Schilsky; Richard M Goldberg
Journal:  Oncologist       Date:  2010-12-10

5.  Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors.

Authors:  Xiaoyun Wu; Shuguang Wu; Wen-Hua Chen
Journal:  J Mol Model       Date:  2011-06-22       Impact factor: 1.810

Review 6.  Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.

Authors:  Beatrix Wulkersdorfer; Markus Zeitlinger; Monika Schmid
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

7.  De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction.

Authors:  Yanmin Zhang; Haichun Liu; Yu Jiao; Haoliang Yuan; Fengxiao Wang; Shuai Lu; Sihui Yao; Zhipeng Ke; Wenting Tai; Yulei Jiang; Yadong Chen; Tao Lu
Journal:  Mol Divers       Date:  2012-10-23       Impact factor: 2.943

8.  Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.

Authors:  Daniel Bexell; Salina Gunnarsson; Ariane Tormin; Anna Darabi; David Gisselsson; Laurent Roybon; Stefan Scheding; Johan Bengzon
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

9.  KIT as a therapeutic target in melanoma.

Authors:  Maria C Garrido; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

10.  Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

Authors:  Sophie de Boüard; Paulette Herlin; James G Christensen; Edwige Lemoisson; Pascal Gauduchon; Eric Raymond; Jean-Sébastien Guillamo
Journal:  Neuro Oncol       Date:  2007-07-10       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.